Clinical Trial Update: Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) [Phase 2]

View source ↗

Summary

A Phase 2 trial (FIGHT-205) comparing Pemigatinib + Pembrolizumab vs Pemigatinib alone vs standard of care in metastatic or unresectable urothelial carcinoma wa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Pemigatinib (pemigatinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2022-05-25